Skip to main content
2022 Guide to Patient Support Services

Kite Pharma

2022 Oncology Guide to Patient Support Services

Kite Pharma/Kite Konnect

844-454-5483

Kite Pharma offers Kite Konnect, a program committed to helping patients and healthcare teams throughout treatment with Tecartus or Yescarta (Table).

Kite Konnect

This program supports healthcare providers and patients throughout each step of treatment with a Kite therapy to include finding CAR T Authorized Treatment Centers, logistics support, reimbursement support, patient therapy enrollment, as well as access to Kite Konnect Case Managers.

Finding a Treatment Center/Patient Enrollment

If you practice at an Authorized Treatment Center, you can enroll your patient for therapy using the Kite Konnect Hospital Portal found at KiteKonnect.com.

For community physicians, you can help your patient take their first step toward treatment by locating an Authorized Treatment Center. To learn more about patient eligibility and to make a referral, please visit the HCP Community Portal found at KiteKonnectrefer.com.

Logistics Support

Patients can learn about potential resources for transportation and housing assistance while on a Kite Pharma therapy. Click here to learn more.

Reimbursement Support

Kite Konnect can help with benefits investigations, claims appeals information, and potential sources of support for eligible uninsured and underinsured patients.

TABLE Kite Pharma Oncology Drugs

Drugs
Indications
Patient support programs

Drug
Tecartus (brexucabtagene autoleucel)
Indications
Treatment of adult patients with relapsed or refractory mantle-cell lymphoma
Patient support program

Drug
Yescarta (axicabtagene ciloleucel)
Indications
Patient support program

Yescarta (axicabtagene ciloleucel) Indications

Treatment of adult patients with relapsed or refractory large B-cell lymphoma after 2 or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma; treatment of adult patients with relapsed or refractory follicular lymphoma after 2 or more lines of systemic therapy

Report Broken Links

Have you encountered a problem with a URL (link) on this page not loading correctly or is displaying an error message?

Help us fix it! Report broken links here.

Report Broken Links

Report Broken Links

*OPM Webpage
Please copy the URL (link) of the OPM webpage you are currently on.
*Broken Link
Please copy the URL (link) to the external webpage that is not displaying content correctly.
Errors include, but are not limited to:
  • "This site can’t be reached"
  • "Hmm. We’re having trouble finding that site."
  • "Hmmm… can't reach this page"
  • "404 Error: Page not found"
Comments
(Optional)